ORIGINAL ARTICLE

Soluble suppression of tumorigenesis-2 is a strong predictor of all-cause, cardiovascular and infection-related mortality risk in haemodialysis patients with diabetes mellitus

Fabian Hammer1,2,3, Bernd Genser4,5, Benjamin Dieplinger6, Margot Egger6, Thomas Müller7, Christiane Drechsler8, Winfried März9, Stefan Störk2,3, Christoph Wanner3,8 and Vera Krane3,8

1Department of Internal Medicine B, Division of Cardiology, University Medicine Greifswald, Greifswald, Germany, 2Department of Internal Medicine I, Division of Cardiology, University Hospital Würzburg, Würzburg, Germany, 3Comprehensive Heart Failure Centre, University Hospital Würzburg, Würzburg, Germany, 4Center for Preventive Medicine and Digital Health Baden-Württemberg, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany, 5BGStats Consulting, Vienna, Austria, 6Department of Laboratory Medicine, Konventhospital Barmherzige Brüder Linz and Ordensklinikum Linz Barmherzige Schwestern, Linz, Austria, 7Department of Laboratory Diagnostics, Hospital of Gmunden, Gmunden, Austria, 8Department of Medicine I, Division of Nephrology, University Hospital Würzburg, Würzburg, Germany and 9Synlab Akademie für ärztliche Fortbildung, Synlab Services GmbH, Mannheim, Germany

Correspondence to: Fabian Hammer; E-mail: fabianhammer@gmx.de

ABSTRACT

Background. Soluble suppression of tumorigenesis-2 (sST2) is a strong prognostic biomarker of cardiovascular (CV) disease. End-stage kidney disease (ESKD) patients are at high risk of CV events and infections. Herein we investigated the utility of sST2 to predict all-cause and cause-specific mortality in haemodialysis (HD) patients with diabetes mellitus.

Methods. sST2 concentrations were measured in plasma samples of 1196 participants of the German Diabetes and Dialysis (4D) study who had type 2 diabetes mellitus and received maintenance HD for ESKD. Hazard ratios (HRs) for prespecified, adjudicated endpoints were determined according to sST2 levels at baseline by multivariate Cox proportional hazards analysis.

Results. Participants (mean age 66 years, 54% male) had a median sST2 concentration of 25 ng/mL and were followed up for 4 years. After adjustment for possible confounders, participants with sST2 concentrations in the highest (> 32.6 ng/mL) compared with the lowest (< 20.1 ng/mL) quartile exhibited a 2-fold higher all-cause mortality risk [HR 2.06 (95% confidence interval (CI) 1.61–2.61); P < .001]. High sST concentrations (fourth versus first quartile) were strongly associated with the risk of cardiac death [HR 2.29 (95% CI 1.55–3.39); P < .001]. Analysis of individual components of cardiac causes of death showed an increased risk of sudden death [HR 2.24 (95% CI 1.33–3.77); P < .001], death due to myocardial infarction [HR 2.12 (95% CI 0.9–5.0); P = .087] and heart failure [HR 3.34 (95% CI 1.15–9.75); P = .027] in

Received: 18.11.2021; Editorial decision: 13.4.2022

© The Author(s) 2022. Published by Oxford University Press on behalf of the ERA. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
participants with sST2 levels in the highest compared with the lowest quartile. Likewise, participants with the highest sST2 levels had an increased risk of fatal stroke [HR 1.92 (95% CI 1.17–3.14); P = .009] and fatal infections [HR 2.01 (95% CI 1.2–3.37); P = .008]. In contrast to fatal CV events, sST2 was not associated with the risk of non-fatal myocardial infarction [HR 0.68 (95% CI 0.41–1.12); P = .132] or non-fatal stroke [HR 1.28 (95% CI 0.64–2.53); P = .485].

Conclusions. In HD patients with diabetes mellitus, high concentrations of sST2 were strongly and independently associated with an increased risk of all-cause mortality, CV mortality and death due to infection but not non-fatal CV events.

GRAPHICAL ABSTRACT

Soluble suppression of tumorigenesis-2 (sST2) is a strong predictor of all-cause, cardiovascular and infection-related mortality risk in haemodialysis patients with diabetes mellitus

Keywords: biomarker, cardiovascular, diabetes mellitus, dialysis, sepsis

INTRODUCTION

In end-stage kidney disease (ESKD), the annual mortality is ~20% and is even higher in haemodialysis (HD) patients with concomitant type 2 diabetes mellitus [1]. In particular, cardiovascular (CV) causes account for about half of all deaths, with sudden cardiac death (SCD) as the most frequent cause, whereas fatal myocardial infarction (MI) and stroke are less common [1, 2]. ESKD patients also carry a high risk of death due to infections, which constitutes the most prevalent non-CV cause of death.

Biomarkers provide a useful tool to estimate prognosis, allowing identification of those patients at highest risk. Suppression of tumorigenesis 2 (ST2) is a member of the interleukin-1 (IL-1) receptor family and exists as a membrane-bound (ST2L) and a soluble (sST2) isoform [3]. IL-33 is the natural ligand to ST2. IL-33/ST2L signalling has several biological functions, both in the CV [4] and immune system [5]. SST2 is not attached to the cell membrane and avidly binds IL-33 and thereby functions as a decoy receptor by disrupting IL-33/ST2L signalling. Over the last decade, circulating levels of sST2 have emerged as a powerful prognostic biomarker, particularly in patients with acute and chronic heart failure [6, 7], but also in ischaemic heart disease [8, 9] and MI [10, 11], pulmonary hypertension [12] and chronic kidney disease (CKD) [13].

We measured sST2 concentrations in 1196 participants of the German Diabetes Dialysis Study (4D) [2]. All study participants had type 2 diabetes mellitus and were on maintenance HD for ESKD. We analysed the association of sST2 with all-cause and disease-specific mortality risk and non-fatal CV event risk.

MATERIALS AND METHODS

Study design and participants

The 4D Study has previously been reported in detail [2]. Briefly, the 4D study was a prospective randomized controlled trial among 1255 patients with type 2 diabetes mellitus, ages 18–80 years, on maintenance HD for <2 years. Between March 1998 and October 2002, patients were recruited in 178 dialysis centres in Germany. After a period of 4 weeks, patients
Table 1. Baseline characteristics of patients stratified by quartiles of sST2 concentrations (Q1–Q4)

| Characteristics | Q1 (n = 299) <20.1 ng/mL | Q2 (n = 299) 20.1–24.9 ng/mL | Q3 (n = 299) 25.0–32.6 ng/mL | Q4 (n = 299) >32.6 ng/mL |
|-----------------|---------------------------|-------------------------------|-------------------------------|---------------------------|
| Age (years)     | 65.8 (8.9)                | 66 (8.2)                     | 66 (8.1)                     | 67 (8.0)                  |
| Male gender, n (%) | 127 (42)               | 152 (51)                     | 177 (59)                     | 193 (65)                  |
| Ever smoking, n (%) | 106 (35)                | 118 (39)                     | 125 (42)                     | 139 (46)                  |
| BMI (kg/m²)     | 28.3 (4.9)                | 28.0 (4.8)                   | 28 (5)                       | 26 (4.4)                  |
| Systolic blood pressure (mmHg) | 145 (22)    | 146 (21)                     | 144 (22)                     | 147 (21)                  |
| Diastolic blood pressure (mmHg) | 76 (10)       | 75 (10)                      | 76 (12)                      | 76 (11)                   |
| Comorbidities, n (%) |                          |                               |                              |                          |
| Arterial hypertension | 266 (89)          | 268 (90)                     | 267 (89)                     | 263 (88)                  |
| Arrhythmia      | 39 (13)                  | 58 (19)                      | 48 (16)                      | 77 (26)                   |
| Peripheral vascular disease | 122 (41)     | 145 (48)                     | 122 (41)                     | 153 (51)                  |
| Ischaemic heart disease | 79 (26)        | 88 (29)                      | 87 (29)                      | 99 (33)                   |
| Chronic heart failure | 82 (27)        | 114 (38)                     | 99 (33)                      | 131 (44)                  |
| Haemoglobin (g/dL) | 10.9 (1.3)          | 11.0 (1.4)                   | 11.0 (1.4)                   | 11 (1.4)                  |
| Haemoglobin A1C (%) | 6.6 (1.2)           | 6.7 (1.3)                    | 6.7 (1.3)                    | 6.9 (1.4)                 |
| Potassium (mmol/L) | 5.3 (0.8)          | 5.2 (0.9)                    | 5.2 (0.8)                    | 5.0 (0.8)                 |
| Phosphate (mmol/L) | 6.0 (1.5)           | 5.9 (1.5)                    | 6.1 (1.5)                    | 6.2 (1.8)                 |
| Albumin (g/dL) | 3.8 (0.3)              | 3.8 (0.3)                    | 3.8 (0.3)                    | 3.8 (0.3)                 |
| C-reactive protein (mg/L, median [IQR]) | 3.6 (7.0) | 5.2 (9.4)                    | 5.1 (10.0)                   | 6.4 (13.6)               |
| NT-proBNP (pg/mL, median [IQR]) | 2245 (5199) | 2958 (5044)                  | 3217 (6659)                  | 5928 (14 470)            |
| Troponin T (ng/mL, median [IQR]) | 0.04 (0.06) | 0.05 (0.06)                  | 0.06 (0.07)                  | 0.07 (0.09)              |
| Cholesterol (mg/dL) | 218 (41)            | 224 (45)                     | 223 (41)                     | 212 (43)                  |
| Duration of diabetes (years) | 17.6 (8.8) | 18.4 (8.9)                   | 17.9 (8.2)                   | 18.5 (8.2)               |
| Dialysis duration (months) | 8.2 (7.1)          | 8.3 (7.0)                    | 7.8 (6.3)                    | 8.7 (7.0)                |

Values are presented as mean (SD) unless stated otherwise.

were randomly assigned to double-blinded treatment with either 20 mg of atorvastatin (n = 619) or placebo (n = 636) once daily. Study visits took place three times before randomization (Visits 1–3), at randomization (Visit 4), at 4 weeks (Visit 5) and every 6 months (Visit 6) after randomization until the date of death, censoring or the end of the study in March 2004. The study complied with the Declaration of Helsinki, was approved by the relevant medical ethics committees and all patients gave written informed consent before inclusion.

Outcomes

The primary endpoint of the 4D study was defined as a composite of death from cardiac causes, fatal or non-fatal stroke and non-fatal MI, whichever occurred first (composite CV endpoint). Death from cardiac causes comprised SCD, fatal MI (death within 28 days after MI), death due to heart failure, death due to coronary heart disease during or within 28 days after intervention and all other deaths ascribed to coronary heart disease. SCD was considered as death verified by terminal rhythm disorders in an electrocardiogram (ECG); by witnesses who observed death within 1 h after the onset of cardiac symptoms; confirmed by autopsy; unexpected death, presumably or possibly of cardiac origin and in the absence of a potassium level ≥7.5 mmol/L before the start of the three most recent sessions of HD. MI was diagnosed when two of the following three criteria were met: typical symptoms, elevated levels of cardiac enzymes or diagnostic changes on the ECG. A stroke was defined as a neurologic deficit lasting ≥24 h. Endpoints were centrally adjudicated according to predefined criteria by three members of the endpoint committee blinded to the study.

Data collection

Information on age, gender and smoking status was obtained through patient interviews. Body mass index (BMI) was calculated as weight (kg) divided by height (m) squared. Smoking status was classified as never, former or current. Comorbidities, including the presence of coronary artery disease and congestive heart failure, as well as the duration of diabetes mellitus and dialysis treatment, were reported by the patients' nephrologists. Coronary artery disease was defined by the history of MI, coronary artery bypass grafting surgery, percutaneous coronary intervention and the presence of coronary heart disease, as documented by coronary angiography. Congestive heart failure was defined according to the classification system of the New York Heart Association. Arrhythmias such as atrial fibrillation or atrial flutter were diagnosed according to an ECG. Blood pressure was measured in the sitting position before the start of the dialysis session.

Laboratory analysis

All blood samples were drawn from study participants before the start of the dialysis session and before the administration of drugs. Levels of sST2 were measured in blood samples taken at baseline at study Visit 3 (1 week before randomization) and stored at −80°C. Plasma was available for the current analysis from 1196/1255 patients. sST2 was measured on a fully automated BEP 2000 instrument (Siemens Healthcare Diagnostics, Marburg, Germany) with the Presage ST2 sandwich immunoassay assay (Critical Diagnostics, San Diego, CA, USA); CVs were <4.0%, as previously described [14].
Statistical analysis

We calculated summary statistics of patient characteristics for subpopulations defined by quartiles of sST2 concentrations. The association of sST2 with clinical endpoints was assessed by multivariable Cox regression analyses calculating adjusted hazard ratios (aHRs) with corresponding 95% confidence intervals (CIs). We fitted different Cox models starting with a univariable (unadjusted) model, followed by a model adjusted for age, sex and treatment allocation (atorvastatin medication; multivariable model 1) and a model (multivariable model 2) additionally adjusted for BMI, cholesterol, phosphate, potassium, atrial fibrillation and peripheral vascular disease. In the core models, sST2 concentrations were coded as a four-level categorical variable reflecting the subpopulations defined by quartiles of sST2 concentrations. In addition, we fitted models using a restricted cubic spline transformation of the sST2 concentrations aimed to visualize the risk association pattern as a function of continuous sST2 exposure. For all covariables included in the Cox models, we graphically checked the condition of the proportional hazards by log-log plots. All hypothesis testing was two-sided considering a P-value of .05 as statistically significant. All statistical analyses were conducted using the statistical software package Stata (version 13; StataCorp, College Station, TX, USA).

RESULTS

From March 1998 to October 2002, 1255 participants were enrolled in the 4D study. The underlying population for this analysis consisted of 1196 participants. The mean age was 66 years [standard deviation (SD) 8.3] and 54% were male. The median sST2 level was 25.0 ng/mL [interquartile range (IQR) 12.5]. Baseline characteristics of study participants according to quartiles of sST2 concentrations are shown in Table 1. Participants with higher sST2 concentrations were of significantly older age, had a higher BMI and were more likely to be male. Further, the prevalence of peripheral vascular disease, atrial fibrillation and heart failure was higher and they had lower phosphate, higher haemoglobin A1c, higher C-reactive protein (CRP) and N-terminal pro-brain natriuretic peptide (NT-proBNP) and troponin T levels (Table 1). During a mean follow-up period of 4.0 years, 586 (49%) participants died; 258 deaths were attributed to cardiac causes, 153 to SCD, 54 to MI, 40 to heart failure and 121 to infectious causes; 157 participants had a non-fatal MI and 66 had a non-fatal stroke.

Baseline sST2 concentrations were strongly associated with all-cause mortality risk (Figure 1A). By multivariable Cox regression analyses adjusted for possible confounders, participants in the highest quartile of sST2 had a 2-fold higher all-cause mortality risk compared with those in the lowest quartile [aHR 2.06 (95% CI 1.61–2.61); P < .001] (Table 2). Almost 45% of all deaths were attributable to cardiac causes, a composite of SCD, fatal MI and death due to heart failure. High sST2 concentrations were strongly associated with the risk of cardiac death (Figure 1B). Participants with sST2 levels in the highest compared with the lowest quartile had a more than 2-fold higher risk of cardiac death [HR 2.29 (95% CI 1.55–3.39); P < .001] (Table 2). Continuous modelling of sST2 levels with all-cause mortality risk (Figure 2A) and cardiac mortality risk (Figure 2B) showed a log-linear association over the entire spectrum of sST2 concentrations [HR increase per sST2 unit: all-cause mortality 1.03 (95% CI 1.020–1.032); P < .001 and cardiac mortality risk 1.03 (95% CI 1.017–1.034); P < .001]. Analysis of the individual components of cardiac causes of death showed similar strong associations with sST2 concentrations: participants in the highest quartile of sST2 concentrations had a >2-fold increased risk of dying from SCD [aHR 2.24 (95% CI 1.33–3.77); P = .002], a more than doubled risk of dying from MI [aHR 2.12 (95% CI 0.90–5.00); P = .087] and a >3-fold increased risk of dying from heart failure [aHR 3.34 (95% CI 1.15–9.75); P = .027] compared with participants in the lowest quartile (Table 2). Besides cardiac causes of death, higher sST2 levels were also associated with an increased risk of fatal stroke [aHR 1.92 (95% CI 1.17–3.14), P = .009]. In contrast to fatal CV events, sST2 showed...
We identified sST2 as an independent prognostic marker of fatal but not non-fatal events in participants of the 4D study who had type 2 diabetes mellitus and were on maintenance HD treatment. Higher levels of sST2 were associated with all-cause mortality as well as cause-specific mortality risk, including SCD, MI, heart failure, stroke and death due to infections. Importantly, extensive adjustments for potential confounders including established biomarkers of CV disease and comorbidities did not materially affect these associations.

The association of high sST2 levels with increased morbidity and mortality risk has been reported for several CV disease entities in non-ESKD patients. High levels of sST2 have been linked with increased mortality risk in acute [15, 16] and chronic heart failure [6, 7]. This association has been shown to be independent of established biomarkers of CV risk such as NT-proBNP and high-sensitivity troponin T [17]. In stable coronary artery disease patients, sST2 predicted long-term all-cause mortality [8] and sudden cardiac death [18], whereas acute MI-elevated sST2 levels were associated with adverse cardiac remodelling [19] and increased risk of CV death, heart failure [11] and short-term survival [10].

More recently the relationship between sST2 and mortality risk was investigated in two reasonably sized HD cohorts. Zhang et al. [20] reported a 1.31 relative risk ratio per 1 SD increase of log-transformed sST2 for all-cause mortality risk and a 2.1 relative risk ratio for CV mortality risk after adjusting for

### DISCUSSION

We identified sST2 as an independent prognostic marker of fatal but not non-fatal events in participants of the 4D study who had type 2 diabetes mellitus and were on maintenance HD treatment. Higher levels of sST2 were associated with all-cause mortality as well cause-specific mortality risk, including SCD, MI, heart failure, stroke and death due to infections. Importantly, extensive adjustments for potential confounders including established biomarkers of CV disease and comorbidities did not materially affect these associations.

The association of high sST2 levels with increased morbidity and mortality risk has been reported for several CV disease entities in non-ESKD patients. High levels of sST2 have been linked with increased mortality risk in acute [15, 16] and chronic heart failure [6, 7]. This association has been shown to be independent of established biomarkers of CV risk such as NT-proBNP and high-sensitivity troponin T [17]. In stable coronary artery disease patients, sST2 predicted long-term all-cause mortality [8] and sudden cardiac death [18], whereas acute MI-elevated sST2 levels were associated with adverse cardiac remodelling [19] and increased risk of CV death, heart failure [11] and short-term survival [10].

More recently the relationship between sST2 and mortality risk was investigated in two reasonably sized HD cohorts. Zhang et al. [20] reported a 1.31 relative risk ratio per 1 SD increase of log-transformed sST2 for all-cause mortality risk and a 2.1 relative risk ratio for CV mortality risk after adjusting for

### Table 2. Univariable and multivariable HRs with 95% CIs for all-cause mortality, cardiac death, death due to heart failure, fatal MI, fatal stroke and death due to infection of subpopulations defined by quartiles (Q) of sST2 concentrations

| sST2 | Q1 (< 20.1 ng/mL) | Q2 (20.1–25 ng/mL) | Q3 (25.1–32.6 ng/mL) | Q4 (> 32.6 ng/mL) |
|------|------------------|--------------------|----------------------|-------------------|
| All-cause mortality (n = 586) | | | | |
| Univariable | 1 1.18 (0.91–1.52) | 2.05 | 1.65 (1.25–2.18) | < .001 | 2.27 (1.79–2.90) | < .001 |
| Model 1 | 1 1.17 (0.91–1.51) | 2.25 | 1.62 (1.24–2.13) | .001 | 2.27 (1.77–2.91) | < .001 |
| Model 2 | 1 1.12 (0.87–1.45) | .371 | 1.64 (1.25–2.16) | < .001 | 2.06 (1.61–2.61) | < .001 |
| Cardiac death (n = 258) | | | | |
| Univariable | 1 1.35 (0.88–2.06) | .172 | 1.87 (1.23–2.85) | .004 | 2.62 (1.78–3.85) | .001 |
| Model 1 | 1 1.34 (0.87–2.06) | .188 | 1.85 (1.20–2.84) | .005 | 2.60 (1.73–3.90) | .001 |
| Model 2 | 1 1.26 (0.83–1.91) | .282 | 1.87 (1.55–3.39) | .001 | 2.29 (1.55–3.39) | .001 |
| Sudden cardiac death (n = 153) | | | | |
| Univariable | 1 1.43 (0.85–2.41) | .175 | 1.85 (1.11–3.10) | .019 | 2.33 (1.41–3.87) | .001 |
| Model 1 | 1 1.46 (0.87–2.46) | .151 | 1.94 (1.14–3.28) | .014 | 2.50 (1.48–4.23) | .002 |
| Model 2 | 1 1.35 (0.80–2.29) | .259 | 2.00 (1.18–3.38) | .010 | 2.24 (1.33–3.77) | .002 |
| Fatal myocardial infarction (n = 54) | | | | |
| Univariable | 1 1.39 (0.61–3.17) | .439 | 1.51 (0.69–3.30) | .301 | 2.61 (1.17–5.80) | .019 |
| Model 1 | 1 1.35 (0.64–3.16) | .495 | 1.42 (0.64–3.16) | .387 | 2.42 (1.05–5.58) | .038 |
| Model 2 | 1 1.26 (0.53–2.98) | .607 | 1.34 (0.59–3.05) | .482 | 2.12 (0.90–5.00) | .087 |
| Death due to heart failure (n = 40) | | | | |
| Univariable | 1 1.22 (0.33–4.66) | .769 | 3.64 (1.21–10.94) | .021 | 5.19 (1.82–14.85) | .002 |
| Model 1 | 1 1.12 (0.30–4.15) | .867 | 3.12 (1.04–9.29) | .042 | 4.26 (1.48–12.28) | .007 |
| Model 2 | 1 1.03 (0.30–3.56) | .958 | 3.02 (1.06–8.61) | .038 | 3.34 (1.15–9.75) | .027 |
| Fatal stroke (n = 94) | | | | |
| Univariable | 1 0.70 (0.37–1.32) | .266 | 1.30 (0.72–2.34) | .379 | 1.57 (0.97–2.55) | .066 |
| Model 1 | 1 0.72 (0.38–1.37) | .318 | 1.46 (0.82–2.60) | .195 | 1.88 (1.13–3.06) | .011 |
| Model 2 | 1 0.72 (0.39–1.33) | .291 | 1.51 (0.85–2.69) | .162 | 1.92 (1.17–3.14) | .009 |
| Death due to infection (n = 121) | | | | |
| Univariable | 1 1.60 (0.86–2.99) | .138 | 1.85 (0.99–3.44) | .052 | 2.43 (1.41–4.20) | .001 |
| Model 1 | 1 1.56 (0.84–2.91) | .159 | 1.75 (0.94–3.28) | .008 | 2.31 (1.35–3.95) | .002 |
| Model 2 | 1 1.50 (0.80–2.83) | .209 | 1.70 (0.91–3.17) | .097 | 2.01 (1.20–3.37) | .008 |

Model 1: adjustments for age, sex and treatment allocation (atorvastatin medication); Model 2: adjustments for age, sex, treatment allocation (atorvastatin medication), BMI, cholesterol, phosphate, potassium, atrial fibrillation and peripheral vascular disease.
NT-proBNP and troponin T in 414 HD patients. Obokata et al. [21] reported an almost 4-fold increase in all-cause mortality risk in 423 HD patients in the high compared with the low sST2 tertile, which was independent of galectin-3 and NT-proBNP. Similar associations of sST2 and mortality risk have also been reported in smaller HD cohorts [13].

Our study differs from and expands upon these reports in several ways: we were able to analyse cause-specific mortality and non-fatal CV events. Further, our study is the largest with the longest follow-up time and centrally adjudicated events according to prespecified criteria. In contrast to previous studies, where the prevalence of diabetes mellitus was reported between 23 and 46% [20–23], all participants of this study had type 2 diabetes [2]. Published data on the effect of diabetes on sST2 levels are inconsistent: in the general population and in patients with heart failure with preserved ejection fraction, the presence of diabetes is not associated with an increased risk in non-fatal CV events [21,43]. However, in contrast to fatal events, higher sST2 levels were not associated with an increased risk in non-fatal CV events in this study. Although surprising, similar observations have been reported in the general population [35, 36] and in other disease entities such as stable coronary artery disease [9] and CKD [37], where sST2 predicted (CV) mortality but not non-fatal CV events. In summary, and in contrast to experimental studies, data from clinical studies do not support the notion that sST2 accelerates atherosclerotic disease and thereby, increases the risk of CV events as such but, importantly, adversely impacts survival following such events.

Apart from CV events, we showed sST2 to be a strong predictor of death due to infection, which constitutes the second most frequent cause of death in HD patients. In non-ESKD patients, high sST2 concentrations have been associated with increased mortality risk in sepsis patients [38, 39]. IL-33 has been shown to orchestrate complex innate and adaptive immune responses [40] and in an experimental sepsis model, administration of IL-33 facilitated neutrophil recruitment and bacterial clearance, suggesting a beneficial role of IL-33/ST2L signalling in bacterial infections [41, 42].

Given that sST2 levels are not affected by dialysis [43] and have a low intra-individual variation [44], sST2 in comparison with NT-proBNP has ideal characteristics as a prognostic biomarker in ESKD patients. Concentrations of sST2 were not particularly high in this study compared with the general population [35, 36]. In fact, 80% of participants had an sST2 concentration within the reference range of the assay (<35 ng/mL), which is in good agreement with previous reports in ESKD patients [21, 43]. However, the prediction of adverse outcomes was not restricted to elevated sST2 levels per se, as we detected a log-linear association of mortality risk over the entire spectrum of sST2 concentrations.

In contrast to heart failure patients, where reductions in sST2 have been established as an indicator of improved outcome [45, 46], the prognostic value of a reduction in sST2 in ESKD has not been investigated so far. Although higher sST2 concentrations are independently associated with increased mortality risk in ESKD patients, the benefit of sST2 measurements in routine clinical practice for individual patients remains to be established, given the lack of a clinical prediction model or the prognostic relevance of serial sST2 measurements [47].
Table 3. Sensitivity analysis to investigate the contribution of three potentially underlying pathophysiological pathways (inflammation, heart failure and cardiac ischaemia) on HRs (highest versus lowest sST2 quartile subgroup) with 95% CIs and outcome

| sST2                      | Q1 (-20.1 ng/mL) | HR (95% CI) | Q4 (-32.6 ng/mL) | HR (95% CI) versus Q1 | P-value versus Q1 |
|---------------------------|------------------|-------------|------------------|-----------------------|-------------------|
| All-cause mortality       | 1                | 2.06 (1.61–2.61) | 2.06 (1.61–2.61) | <.001                 |
| + adj. for inflammation   | 1                | 1.87 (1.48–2.37) |                 | <.001                 |
| + adj. for heart failure  | 1                | 1.81 (1.42–2.30) |                 | <.001                 |
| + adj. for cardiac ischaemia | 1            | 1.98 (1.55–2.54) |                 | <.001                 |
| Cardiac Death             | 1                | 2.29 (1.55–3.39) |                 | .001                  |
| + adj. for inflammation   | 1                | 2.12 (1.42–3.17) |                 | .001                  |
| + adj. for heart failure  | 1                | 2.03 (1.37–3.02) |                 | .001                  |
| + adj. for cardiac ischaemia | 1           | 2.26 (1.51–3.38) |                 | .001                  |
| Sudden cardiac death      | 1                | 2.24 (1.33–3.77) |                 | .002                  |
| + adj. for inflammation   | 1                | 2.05 (1.20–3.51) |                 | .009                  |
| + adj. for heart failure  | 1                | 1.94 (1.13–3.33) |                 | .017                  |
| + adj. for cardiac ischaemia | 1            | 2.34 (1.40–3.92) |                 | .001                  |
| Fatal myocardial infarction| 1              | 2.12 (0.90–5.00) |                 | .087                  |
| + adj. for inflammation   | 1                | 2.03 (0.85–4.82) |                 | .066                  |
| + adj. for heart failure  | 1                | 2.09 (0.88–4.97) |                 | .094                  |
| + adj. for cardiac ischaemia | 1            | 2.00 (0.83–4.80) |                 | .123                  |
| Death due to heart failure| 1                | 3.34 (1.15–9.75) |                 | .027                  |
| + adj. for inflammation   | 1                | 2.82 (0.97–8.18) |                 | .056                  |
| + adj. for heart failure  | 1                | 2.95 (1.05–8.32) |                 | .041                  |
| + adj. for cardiac ischaemia | 1            | 2.91 (0.97–8.77) |                 | .058                  |
| Fatal stroke              | 1                | 1.92 (1.17–3.14) |                 | .009                  |
| + adj. for inflammation   | 1                | 2.01 (0.97–4.17) |                 | .062                  |
| + adj. for heart failure  | 1                | 2.04 (0.91–4.55) |                 | .084                  |
| + adj. for cardiac ischaemia | 1            | 2.01 (0.97–4.17) |                 | .007                  |
| Death due to infection    | 1                | 2.01 (1.20–3.37) |                 | .008                  |
| + adj. for inflammation   | 1                | 1.72 (1.03–2.90) |                 | .040                  |
| + adj. for heart failure  | 1                | 1.70 (0.99–2.91) |                 | .053                  |
| + adj. for cardiac ischaemia | 1            | 1.90 (1.12–3.23) |                 | .018                  |

Note: Core estimates refer to Model 2 adjusted for age, sex, treatment allocation (atorvastatin medication), BMI, cholesterol, phosphate, potassium, atrial fibrillation and peripheral vascular disease. Additional adjustments (adj.) for the following models were inflammation: C-reactive protein; heart failure: diagnosis of chronic heart failure and levels of BNP; ischaemic heart disease: diagnosis of coronary artery disease and troponin T levels.

In summary, we found sST2 to be a strong and independent predictor of fatal events in a large cohort of HD patients with type 2 diabetes mellitus. The prognostic utility was not only related to CV causes of death, but also to death due to infection, whereas sST2 concentrations did not predict non-fatal CV events.

Strengths and limitations

Strengths of our study are the large number of participants, the prospective study design, central adjudication of outcome measures according to pre specified criteria and the long period of follow-up. Limitations include that this was a post hoc analysis of a selected cohort of German HD patients with type 2 diabetes mellitus and thus the relationship between sST2 and increased mortality risk may not be generalizable to other patient populations. Despite the extensive adjustments for several confounding factors, residual confounding cannot be excluded. Finally, causality cannot be deduced from observational data.

CONFLICT OF INTEREST STATEMENT

The results presented in this work have not been published previously in whole or part, except in abstract format. F.H. reports grants from the German Ministry for Education and Research and speaker honoraria/consultation fees from Novartis, Daiichi Sankyo® and Vifor. S.S. reports grants from the German Ministry for Education and Research, research grants from Bayer and Boehringer and speaker honoraria/consultation fees from AstraZeneca, Bayer, Boehringer Ingelheim, Novartis, Pfizer, Sanofi and Servier, all outside the submitted work. C.W. is member of the CKJ editorial board. C.W. received grant support and honoraria outside of the present trial from Boehringer Ingelheim, Idorsia and Sanofi-Genzyme and honoraria from AstraZeneca, Bayer, Chiesi, FMC, Gilead, GlaxoSmithKline, Eli Lilly, MSD and Vifor. B.G., B.D., M.E., T.M., C.D., W.M. and V.K. have nothing to disclose.

DATA AVAILABILITY STATEMENT

The data underlying this article will be shared upon reasonable request to the corresponding author.
REFERENCES

1. Saran R, Robinson B, Abbott KC et al. US Renal Data System 2017 annual data report: epidemiology of kidney disease in the united states. Am J Kidney Dis 2018; 71: A7

2. Wanner C, Krane V, Marz W et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238–248

3. De la Fuente M, MacDonald TT, Hermoso MA. The IL-33/ST2 axis: role in health and disease. Cytokine Growth Factor Rev 2015; 26: 615–623

4. Pascual-Figal DA, Januzzi JL. The biology of ST2: the interna-

3. De la Fuente M, MacDonald TT, Hermoso MA. The IL-33/ST2

eal role of the interleukin-33/ST2 axis in infectious diseases. Infect Immun 2015; 83: 1738–1748

5. Ky B, French B, McCloskey K et al. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail 2011; 4: 180–187

7. Bayes-Genis A, de Antonio M, Galan A et al. Combined use of high-sensitivity ST2 and NTproBNP to improve the prediction of death in heart failure. Eur J Heart Fail 2012; 14: 32–38

8. Dieplinger B, Egger M, Haltmayer M et al. Increased soluble ST2 predicts long-term mortality in patients with stable coronary artery disease: results from the Ludwigshafen Risk and Cardiovascular Health Study. Clin Chem 2014; 60: 530–540

9. Pfetsch V, Sanín V, Jenaesch A et al. Increased plasma concentrations of soluble ST2 independently predict mortality but not cardiovascular events in stable coronary heart disease patients: 13-year follow-up of the KAROLA study. Cardiovasc Drugs Ther 2017; 31: 167–177

10. Shimpoo M, Morrow DA, Weinberg EO et al. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation 2004; 109: 2186–2190

11. Sabatine MS, Morrow DA, Higgins LJ et al. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation 2008; 117: 1936–1944

12. Placido R, Cortez-Dias N, Robalo Martins S et al. Prognostic stratification in pulmonary hypertension: a multibiomarker approach. Rev Port Cardiol 2017; 36: 111–125

13. Guo G, Huang A, Huang X et al. Prognostic value of soluble suppression of tumorigenicity 2 in chronic kidney disease patients: a meta-analysis. Dis Markers 2021; 2021: 888193

14. Dieplinger B, Januzzi JL, Jr, Steinmair M et al. Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma—the presage ST2 assay. Clin Chim Acta 2009; 409: 33–40

15. Rehman SU, Mueller T, Januzzi JL, Jr. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J Am Coll Cardiol 2008; 52: 1458–1465

16. Mueller T, Dieplinger B, Gegenhuber A et al. Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure. Clin Chem 2008; 54: 752–756

17. Emdin M, Aimo A, Vergaro G et al. sST2 predicts outcome in chronic heart failure beyond NT-proBNP and high-sensitivity troponin T. J Am Coll Cardiol 2018; 72: 2309–2320

18. Lepojarvi ES, Huikuri HV, Piira OP et al. Biomarkers as predictors of sudden cardiac death in coronary artery disease patients with preserved left ventricular function (ARTEMIS study). PloS One 2018; 13: e0203363

19. Weir RA, Miller AM, Murphy GE et al. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J Am Coll Cardiol 2010; 55: 243–250

20. Zhang Z, Shen B, Cao X et al. Increased soluble suppression of tumorigenicity 2 level predicts all-cause and cardiovascular mortality in maintenance hemodialysis patients: a prospective cohort study. Blood Purif 2017; 43: 37–45

21. Obokata M, Sunaga H, Ishida H et al. Independent and incremental prognostic value of novel cardiac biomarkers in chronic hemodialysis patients. Am Heart J 2016; 179: 29–41

22. Homans E, Ekart R. ST2 as a novel prognostic marker in end-stage renal disease patients on hemodialfiltration. Clin Chim Acta 2018; 477: 105–112

23. Wang Z, Chen Z, Yu H et al. Superior prognostic value of soluble suppression of tumorigenicity 2 for the short-term mortality of maintenance hemodialysis patients compared with NT-proBNP: a prospective cohort study. Ren Fail 2020; 42: 523–530

24. Coglianese EE, Larson MG, Vasan RS et al. Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study. Clin Chem 2012; 58: 1673–1681

25. Rudyk IS, Medentsvea OQ, Gasanov IC et al. Influence of various risk factors on the level of ST2 biomarker in patients with heart failure and diabetes mellitus type 2. Pol Merkur Lekarski 2021; 49: 95–98

26. Alonso N, Lupon J, Baralid J et al. Impact of diabetes on the predictive value of heart failure biomarkers. Cardiovasc Diabetol 2016; 15: 151

27. Weinberg EO, Shimpoo M, Hurwitz S et al. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 2003; 107: 721–726

28. Demyanets S, Kaun C, Pents R et al. Components of the interleukin-33/ST2 system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature. J Mol Cell Cardiol 2013; 60: 16–26

29. Sanada S, Hakuno D, Higgins LJ et al. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 2007; 117: 1538–1549

30. Seki K, Sanada S, Kudinova AY et al. Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circ Heart Fail 2009; 2: 684–691

31. Chen WY, Hong J, Gannon J et al. Myocardial pressure overload induces systemic inflammation through endothelial cell IL-33. Proc Natl Acad Sci USA 2015; 112: 7249–7254

32. Veeraivedu PT, Sanada S, Okuda K et al. Ablation of IL-33 gene exacerbate myocardial remodeling in mice with heart failure induced by mechanical stress. Biochem Pharmacol 2017; 138: 73–80

33. Miller AM, Xu D, Asquith DL et al. IL-33 reduces the development of atherosclerosis. J Exp Med 2008; 205: 339–346

34. McLaren JE, Michael DR, Saltcr RC et al. IL-33 reduces macrophage foam cell formation. J Immunol 2010; 185: 1222–1229

35. Hughes MF, Appelbaum S, Havulinna AS et al. ST2 may not be a useful predictor for incident cardiovascular events, heart failure and mortality. Heart 2014; 100: 1715–1721

36. Wang TJ, Wollert KC, Larson MG et al. Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study. Circulation 2012; 126: 1596–1604
37. Tuegel C, Katz R, Alam M et al. GDF-15, galectin 3, soluble ST2, and risk of mortality and cardiovascular events in CKD. Am J Kidney Dis 2018; 72: 519–528
38. Hoogerwerf JJ, Tanck MW, van Zoelen MA et al. Soluble ST2 plasma concentrations predict mortality in severe sepsis. Intensive Care Med 2010; 36: 630–637
39. Krychtiuk KA, Stojkovic S, Lenz M et al. Predictive value of low interleukin-33 in critically ill patients. Cytokine 2018; 103: 109–113
40. Miller AM. Role of IL-33 in inflammation and disease. J Inflamm (Lond) 2011; 8: 22
41. Alves-Filho JC, Sonego F, Souto FO et al. Interleukin-33 attenuates sepsis by enhancing neutrophil influx to the site of infection. Nat Med 2010; 16: 708–712
42. Lan F, Yuan B, Liu T et al. Interleukin-33 facilitates neutrophil recruitment and bacterial clearance in S. aureus-caused peritonitis. Mol Immunol 2016; 72: 74–80
43. Mueller T, Gegenhuber A, Kronabethleitner G et al. Plasma concentrations of novel cardiac biomarkers before and after hemodialysis session. Clin Biochem 2015; 48: 1163–1166
44. Wu AH, Wians F, Jaffe A. Biological variation of galectin-3 and soluble ST2 for chronic heart failure: implication on interpretation of test results. Am Heart J 2013; 165: 995–999
45. Gaggin HK, Szymonifka J, Bhardwaj A et al. Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin t measurements in patients with chronic heart failure. JACC Heart Fail 2014; 2: 65–72
46. O’Meara E, Prescott MF, Claggett B et al. Independent prognostic value of serum soluble ST2 measurements in patients with heart failure and a reduced ejection fraction in the PARADIGM-HF trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure). Circ Heart Fail 2018; 11: e004446
47. Meijers WC, Bayes-Genis A, Mebazaa A et al. Circulating heart failure biomarkers beyond natriuretic peptides: review from the biomarker study group of the Heart Failure Association (HFA), European Society of Cardiology (ESC). Eur J Heart Fail 2021; 23: 1610–1632